Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Pre-Transplant R-Bendamustine Induces High Rates of Minimial Residual Disease in MCL Patients: Updated Results of S1106: US Intergroup Study of a Randomized Phase II Trial of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplants for Patients with Mantle Cell Lymphoma

Blood (2015) 126 (23): 518.

https://doi.org/10.1182/blood.V126.23.518.518

Published: 2015

Journal Articles

Outpatient Administration of High Dose BEAM Chemotherapy As Conditioning for Autologous Stem Cell Transplantation for Lymphoma Results in Fewer Infectious Complications and Improved Survival

Robin M. Reid, MD, Andrea Baran, MS, Paul M. Barr, MD, Michael W. Becker, MD, Steven H. Bernstein, MD, Jonathan W. Friedberg, MD, Jane L. Liesveld, MD, Gordon L. Phillips, MD, Lucy Wedow, FNP, Laurie A. Milner, MD

Blood (2014) 124 (21): 3984.

https://doi.org/10.1182/blood.V124.21.3984.3984

Published: 2014

Journal Articles

Phase II Trial of R-CHOP Plus Bortezomib Induction Therapy Followed By Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601

Brian G. Till, MD, Hongli Li, M.S., Steven H. Bernstein, MD, Richard I. Fisher, MD, Richard Burack, MDPhD, Lisa M. Rimsza, MD, Justin Floyd, DO, Marco A. DaSilva, MD, Dennis F. Moore, MD, Michael LeBlanc, PhD, Jonathan W. Friedberg, MD

Blood (2014) 124 (21): 149.

https://doi.org/10.1182/blood.V124.21.149.149

Published: 2014

Journal Articles

Redox Associated Gene Expression Predicts For Responses To The Pro-Oxidant Molecule Imexon In Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma: Results Of a Multi-Center Phase II Study

Paul M. Barr, MD, Margaret M. Briehl, PhD, Steven H Bernstein, MD, Jonathan W. Friedberg, MD, Andrea Baran, MS, Derick R. Peterson, PhD, Daniel Oscar Persky, MD, Carla Casulo, MD, Megan M. Herr, BS, Jamie Littleton, BSN, Erin Cebula, MPH, CCRP, Mark Schwartz, PhD, Soham D. Puvvada, MD, Robert T Dorr, PhD, Richard I Fisher, MD, Thomas P. Miller, MD

Blood (2013) 122 (21): 89.

https://doi.org/10.1182/blood.V122.21.89.89

Published: 2013

Journal Articles

The Transcriptional Profile of Follicular Lymphoma Associated Regulatory T-Cells (Tregs) Is More Consistent with Tregs Having a Germinal Center Localization and the Ability to Suppress Follicular Helper T-Cells

Shannon P. Hilchey, PhD, Alexander F. Rosenberg, PhD, Stephen L. Welle, PhD, Ollivier Hyrien, PhD, Steven H. Bernstein, MD

Blood (2012) 120 (21): 1536.

https://doi.org/10.1182/blood.V120.21.1536.1536

Published: 2012

Journal Articles

Mesenchymal Stromal Cells Support Follicular Lymphoma-Associated Follicular Helper T-Cells, in Part, Through an IL-6 and IL-21-Dependent Mechanism.

Michael T. Brady, PhD, Shannon P. Hilchey, PhD, Steven H. Bernstein, MD

Blood (2012) 120 (21): 2707.

https://doi.org/10.1182/blood.V120.21.2707.2707

Published: 2012

Journal Articles

The Rheumatoid Arthritis Drug Auranofin Has Significant in Vitro Activity in MCL and DLCL and Is Synergistic with a Glutathione Depleting Agent

Jolanta Skalska, PhD, Michelle M. Kiebala, PhD, Shannon P. Hilchey, PhD, Yun Dai, MD, PhD, Steven Grant, MD, Paul S. Brookes, PhD, Derick R. Peterson, PhD, Sanjay B. Maggirwar, PhD, Steven H. Bernstein, MD

Blood (2012) 120 (21): 1658.

https://doi.org/10.1182/blood.V120.21.1658.1658

Published: 2012

Journal Articles

Comprehensive in Vitro and in Vivo Analysis of Phosphatidylinositol-3-Kinase Delta (PI3Kδ) Inhibition Using GS-1101 (CAL-101) in Combination with Mammalian Target of Rapamycin (mTOR) Inhibition Using Temsirolimus or Everolimus in Mantle Cell Lymphoma (MCL)

Paul M. Barr, MD, Francisco J. Hernandez-Ilizaliturri, MD, Thomas Murante, BS, Shannon P. Hilchey, PhD, Derick R Peterson, PhD, Jennifer L. Kelly, PhD, MPH, Dave M. Johnson, Brian J. Lannutti, PhD, Myron S. Czuczman, MD, Jonathan W. Friedberg, MD, Steven H. Bernstein, MD

Blood (2012) 120 (21): 3719.

https://doi.org/10.1182/blood.V120.21.3719.3719

Published: 2012

Journal Articles

Follicular Lymphoma Tumor Infiltrating T-Helper (Th) Cells Have the Same Intrinsic Polyfunctional Response Potential Upon Stimulation as Do Reactive and Normal Lymph Node Th Cells Despite Having Skewed Differentiation; Implications for Immunotherapy

Shannon P. Hilchey, PhD, Alexander F. Rosenberg, PhD, Ollivier Hyrien, PhD, Shelley Secor-Socha, Matthew R. Cochran, W. Richard Burack, MD, PhD, Jyh-Chiang E. Wang, PhD, Sally A. Quataert, PhD, Steven H. Bernstein, MD

Blood (2010) 116 (21): 3119.

https://doi.org/10.1182/blood.V116.21.3119.3119

Published: 2010

Journal Articles

High-Dose Therapy and Autologous Stem Cell Transplant (HD-ASCT) for Transformed Non-Hodgkin Lymphoma (NHL) In the Rituximab Era

Makiko Ban-Hoefen, MD, Jonathan W. Friedberg, MD, Jennifer L. Kelly, PhD, MPH, Steven H. Bernstein, MD, Jane L. Liesveld, MD, Faith Young, MD, Richard I Fisher, MD, Louis Constine, MD, Michael Becker, MD, Gordon L. Phillips, II, MD

Blood (2010) 116 (21): 2393.

https://doi.org/10.1182/blood.V116.21.2393.2393

Published: 2010

Journal Articles

Modulation of Cell Surface Protein Free Thiols; A Potential Novel Mechanism of Action of the Sesquiterpene Lactone Parthenolide in Non-Hodgkin's Lymphoma.

Jolanta Skalska, PhD, Paul S Brookes, PhD, S. M Nadtochy, Shannon Hilchey, PhD, Craig T. Jordan, PhD, Monica L. Guzman, PhD, Sanjay Maggirwar, PhD, Margaret M Briehl, PhD, Steven H. Bernstein, MD

Blood (2009) 114 (22): 3774.

https://doi.org/10.1182/blood.V114.22.3774.3774

Published: 2009

Journal Articles

The Triterpenoid 2-Cyano-3,12-Dioxooleana-1,9-Dien-28-Oic Acid and Its Derivatives Inhibit Mitochondrial Lon Protease Activity: A Potential Novel Pathway for the Induction of Lymphoma Cell Death.

Steven H. Bernstein, MD, Bin Lin, PhD, Shannon Hilchey, PhD, N. Villaluna, L. Chen, K. Madura, Kim Morse, Hollie Metcalf, Michael Andreeff, MD, PhD, Paul S Brookes, PhD, Carolyn K Suzuki, PhD

Blood (2009) 114 (22): 414.

https://doi.org/10.1182/blood.V114.22.414.414

Published: 2009

Journal Articles

Increased Proportions of CD39 + Infiltrating T-Cells Contribute to Adenosine Mediated T-Cell Hypo-Responsiveness within Human Follicular Lymphoma.

Shannon P. Hilchey, PhD, James J. Kobie, PhD, Matthew R. Cochran, Shelley Secor-Socha, Jyh-Chiang E. Wang, Ollivier Hyrien, PhD, W. Richard Burack, MD, PhD, Tim R. Mosmann, PhD, Sally A. Quataert, PhD, Steven H. Bernstein, MD

Blood (2009) 114 (22): 758.

https://doi.org/10.1182/blood.V114.22.758.758

Published: 2009

Journal Articles

Detailed Phenotypic Characterization of T-Cell Populations in Reactive, Normal and Follicular Lymphoma Nodes: Elevation of Follicular B Helper T-Cell Subsets in Follicular Lymphoma.

Shannon P. Hilchey, PhD, Shelley Secor-Socha, Matthew R. Cochran, Ollivier Hyrien, PhD, W. Richard Burack, MD, PhD, Jyh-Chiang E. Wang, Sally A. Quataert, Steven H. Bernstein, MD

Blood (2009) 114 (22): 2948.

https://doi.org/10.1182/blood.V114.22.2948.2948

Published: 2009

Journal Articles

Early Stage Diffuse Large B Cell Lymphoma (DLBCL) in the CHOP-R Era: Does Involved Field Radiation Therapy (IFRT) Impact Outcome?.

Manzurul A. Sikder, MD, Sughosh Dhakal, Jennifer Kelly, MPH, Steven H. Bernstein, MD, Faith Young, MD, Richard I. Fisher, MD, Jonathan Friedberg, MD, Louis Constine, MD

Blood (2007) 110 (11): 3433.

https://doi.org/10.1182/blood.V110.11.3433.3433

Published: 2007

Journal Articles

SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).

Blood (2006) 108 (11): 2718.

https://doi.org/10.1182/blood.V108.11.2718.2718

Published: 2006

Journal Articles

Follicular Lymphoma Infiltrating CD4 + CD25 + GITR + Regulatory T-Cells Are Potent Suppressors of CD3/CD28 Co-Stimulated Autologous and Allogeneic CD8 + CD25 − and CD4 + CD25 − T-Cells.

Shannon P. Hilchey, PhD, Richard B. Bankert, Ph.D., Lisa M. Rimsza, MD, Steven H. Bernstein, MD

Blood (2006) 108 (11): 3681.

https://doi.org/10.1182/blood.V108.11.3681.3681

Published: 2006

Journal Articles

Phase I Study of Cladribine, Cytarabine (Ara-C), Granulocyte Colony Stimulating Factor (G-CSF) (CLAG Regimen) and Simultaneous Escalating Doses of Imatinib Mesylate (Gleevec) in Relapsed/Refractory AML.

Camille N. Abboud, MD, Alison Walker, MD, Rami S. Komrokji, MD, Jainulabdeen J. Ifthikharuddin, MD, Connie Sparks, BS,CRA, Kelly Likly, MSN, Patti Messina, BSN, Deborah Mulford, MD, Jonathan Friedberg, MD, Michael W. Becker, MD, Faith Young, MD, Steven H. Bernstein, MD, August J. Salvado, MD, Gordon L. Phillips, MD, Jane L. Liesveld, MD

Blood (2006) 108 (11): 1958.

https://doi.org/10.1182/blood.V108.11.1958.1958

Published: 2006

Journal Articles

Phase I Study for Poor Prognosis Lymphoma: Modification of the “BEAM” (BCNU +Etoposide+ARA-C+Melphalan) Regimen with Escalating-Dose Melphalan (MEL) Using Amifostine (AF) Cytoprotection and Autologous Hematopoietic Stem Cell Transplantation (AHSCT).

Gordon L. Phillips, MD, Camille N. Abboud, MD, Steven H. Bernstein, MD, Jonathan W. Friedberg, MD, Michael W. Becker, MD, Jainulabdeen J. Ifthikharuddin, MD, Faith Young, MD, Jane L. Liesveld, MD

Blood (2006) 108 (11): 3076.

https://doi.org/10.1182/blood.V108.11.3076.3076

Published: 2006

Journal Articles

SGN-30 (Anti-CD30 Monoclonal Antibody) Is Active and Well Tolerated in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).

Andres Forero-Torres, MD, Steven H. Bernstein, MD, Ajay K. Gopal, MD, Francine Foss, MD, John P. Leonard, MD, Joseph D. Rosenblatt, MD, Nancy L. Bartlett, MD, Bruce D. Cheson, MD, Elliott Epner, MD, Francisco J. Hernandez-Illizaliturri, MD, Stephen J. Proctor, MD, Pauline Brice, MD, Harve Tilly, MD, Corinne Haioun, MD, Mats Jerkeman, MD, Andre Bosly, MD, Jennie M. Lorenz, Jeremy Barton, MD

Blood (2005) 106 (11): 3356.

https://doi.org/10.1182/blood.V106.11.3356.3356

Published: 2005

NARROW

Pre-Transplant R-Bendamustine Induces High Rates of Minimial Residual Disease in MCL Patients: Updated Results of S1106: US Intergroup Study of a Randomized Phase II Trial of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplants for Patients with Mantle Cell Lymphoma

Outpatient Administration of High Dose BEAM Chemotherapy As Conditioning for Autologous Stem Cell Transplantation for Lymphoma Results in Fewer Infectious Complications and Improved Survival

Phase II Trial of R-CHOP Plus Bortezomib Induction Therapy Followed By Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601

Redox Associated Gene Expression Predicts For Responses To The Pro-Oxidant Molecule Imexon In Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma: Results Of a Multi-Center Phase II Study

The Transcriptional Profile of Follicular Lymphoma Associated Regulatory T-Cells (Tregs) Is More Consistent with Tregs Having a Germinal Center Localization and the Ability to Suppress Follicular Helper T-Cells

Mesenchymal Stromal Cells Support Follicular Lymphoma-Associated Follicular Helper T-Cells, in Part, Through an IL-6 and IL-21-Dependent Mechanism.

The Rheumatoid Arthritis Drug Auranofin Has Significant in Vitro Activity in MCL and DLCL and Is Synergistic with a Glutathione Depleting Agent

Comprehensive in Vitro and in Vivo Analysis of Phosphatidylinositol-3-Kinase Delta (PI3Kδ) Inhibition Using GS-1101 (CAL-101) in Combination with Mammalian Target of Rapamycin (mTOR) Inhibition Using Temsirolimus or Everolimus in Mantle Cell Lymphoma (MCL)

Follicular Lymphoma Tumor Infiltrating T-Helper (Th) Cells Have the Same Intrinsic Polyfunctional Response Potential Upon Stimulation as Do Reactive and Normal Lymph Node Th Cells Despite Having Skewed Differentiation; Implications for Immunotherapy

High-Dose Therapy and Autologous Stem Cell Transplant (HD-ASCT) for Transformed Non-Hodgkin Lymphoma (NHL) In the Rituximab Era

Modulation of Cell Surface Protein Free Thiols; A Potential Novel Mechanism of Action of the Sesquiterpene Lactone Parthenolide in Non-Hodgkin's Lymphoma.

The Triterpenoid 2-Cyano-3,12-Dioxooleana-1,9-Dien-28-Oic Acid and Its Derivatives Inhibit Mitochondrial Lon Protease Activity: A Potential Novel Pathway for the Induction of Lymphoma Cell Death.

Increased Proportions of CD39 + Infiltrating T-Cells Contribute to Adenosine Mediated T-Cell Hypo-Responsiveness within Human Follicular Lymphoma.

Detailed Phenotypic Characterization of T-Cell Populations in Reactive, Normal and Follicular Lymphoma Nodes: Elevation of Follicular B Helper T-Cell Subsets in Follicular Lymphoma.

Early Stage Diffuse Large B Cell Lymphoma (DLBCL) in the CHOP-R Era: Does Involved Field Radiation Therapy (IFRT) Impact Outcome?.

SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).

Follicular Lymphoma Infiltrating CD4 + CD25 + GITR + Regulatory T-Cells Are Potent Suppressors of CD3/CD28 Co-Stimulated Autologous and Allogeneic CD8 + CD25 − and CD4 + CD25 − T-Cells.

Phase I Study of Cladribine, Cytarabine (Ara-C), Granulocyte Colony Stimulating Factor (G-CSF) (CLAG Regimen) and Simultaneous Escalating Doses of Imatinib Mesylate (Gleevec) in Relapsed/Refractory AML.

Phase I Study for Poor Prognosis Lymphoma: Modification of the “BEAM” (BCNU +Etoposide+ARA-C+Melphalan) Regimen with Escalating-Dose Melphalan (MEL) Using Amifostine (AF) Cytoprotection and Autologous Hematopoietic Stem Cell Transplantation (AHSCT).

SGN-30 (Anti-CD30 Monoclonal Antibody) Is Active and Well Tolerated in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only